Answer
Women using systemically acting hormonal contraception while taking VITRAKVI (larotrectinib sulfate) should add a barrier method because it is unknown whether larotrectinib may reduce the contraceptive's effectiveness.
Sources for this answer
- Vitrakvi 25 mg hard capsulesBayer plc · emc · SmPC §4.5 Interaction with other medicinal products · Version 14Document updated
Sources checked